1303 related articles for article (PubMed ID: 24942694)
1. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease.
Strober W; Asano N; Fuss I; Kitani A; Watanabe T
Immunol Rev; 2014 Jul; 260(1):249-60. PubMed ID: 24942694
[TBL] [Abstract][Full Text] [Related]
2. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease.
Simms LA; Doecke JD; Walsh MD; Huang N; Fowler EV; Radford-Smith GL
Gut; 2008 Jul; 57(7):903-10. PubMed ID: 18305068
[TBL] [Abstract][Full Text] [Related]
3. Host-microbe interaction: mechanisms of defensin deficiency in Crohn's disease.
Wang G; Stange EF; Wehkamp J
Expert Rev Anti Infect Ther; 2007 Dec; 5(6):1049-57. PubMed ID: 18039087
[TBL] [Abstract][Full Text] [Related]
4. Defensin-immunology in inflammatory bowel disease.
Wehkamp J; Stange EF; Fellermann K
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S137-44. PubMed ID: 20117337
[TBL] [Abstract][Full Text] [Related]
5. Crohn's disease: a role of gut microbiota and Nod2 gene polymorphisms in disease pathogenesis.
Hrnčířová L; Krejsek J; Šplíchal I; Hrnčíř T
Acta Medica (Hradec Kralove); 2014; 57(3):89-96. PubMed ID: 25649363
[TBL] [Abstract][Full Text] [Related]
6. [Barrier- and autophagic functions of the intestinal epithelia: role of disturbances in the pathogenesis of Crohn's disease].
Lapis K
Orv Hetil; 2010 Oct; 151(40):1645-55. PubMed ID: 20860961
[TBL] [Abstract][Full Text] [Related]
7. NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease.
Peyrin-Biroulet L; Chamaillard M
J Endotoxin Res; 2007; 13(3):135-9. PubMed ID: 17621555
[TBL] [Abstract][Full Text] [Related]
8. The molecular basis of NOD2 susceptibility mutations in Crohn's disease.
Strober W; Kitani A; Fuss I; Asano N; Watanabe T
Mucosal Immunol; 2008 Nov; 1 Suppl 1(0 1):S5-9. PubMed ID: 19079230
[TBL] [Abstract][Full Text] [Related]
9. Regulation of human enteric α-defensins by NOD2 in the Paneth cell lineage.
Tan G; Zeng B; Zhi FC
Eur J Cell Biol; 2015 Jan; 94(1):60-6. PubMed ID: 25433720
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory bowel disease: an impaired barrier disease.
Jäger S; Stange EF; Wehkamp J
Langenbecks Arch Surg; 2013 Jan; 398(1):1-12. PubMed ID: 23160753
[TBL] [Abstract][Full Text] [Related]
11. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.
Wehkamp J; Harder J; Weichenthal M; Schwab M; Schäffeler E; Schlee M; Herrlinger KR; Stallmach A; Noack F; Fritz P; Schröder JM; Bevins CL; Fellermann K; Stange EF
Gut; 2004 Nov; 53(11):1658-64. PubMed ID: 15479689
[TBL] [Abstract][Full Text] [Related]
12. Dysbiotic gut microbiome: A key element of Crohn's disease.
Øyri SF; Műzes G; Sipos F
Comp Immunol Microbiol Infect Dis; 2015 Dec; 43():36-49. PubMed ID: 26616659
[TBL] [Abstract][Full Text] [Related]
13. Nod2 is essential for temporal development of intestinal microbial communities.
Rehman A; Sina C; Gavrilova O; Häsler R; Ott S; Baines JF; Schreiber S; Rosenstiel P
Gut; 2011 Oct; 60(10):1354-62. PubMed ID: 21421666
[TBL] [Abstract][Full Text] [Related]
14. A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis.
Agius LM
J Theor Biol; 2004 Mar; 227(2):219-28. PubMed ID: 14990386
[TBL] [Abstract][Full Text] [Related]
15. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense.
Wehkamp J; Stange EF
Ann N Y Acad Sci; 2006 Aug; 1072():321-31. PubMed ID: 17057212
[TBL] [Abstract][Full Text] [Related]
16. Nod2: a key regulator linking microbiota to intestinal mucosal immunity.
Biswas A; Petnicki-Ocwieja T; Kobayashi KS
J Mol Med (Berl); 2012 Jan; 90(1):15-24. PubMed ID: 21861185
[TBL] [Abstract][Full Text] [Related]
17. Defensins and inflammation: the role of defensins in inflammatory bowel disease.
Ramasundara M; Leach ST; Lemberg DA; Day AS
J Gastroenterol Hepatol; 2009 Feb; 24(2):202-8. PubMed ID: 19215333
[TBL] [Abstract][Full Text] [Related]
18. Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli.
Kullberg BJ; Ferwerda G; de Jong DJ; Drenth JP; Joosten LA; Van der Meer JW; Netea MG
Immunology; 2008 Apr; 123(4):600-5. PubMed ID: 18028374
[TBL] [Abstract][Full Text] [Related]
19. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease.
Wehkamp J; Schmid M; Fellermann K; Stange EF
J Leukoc Biol; 2005 Apr; 77(4):460-5. PubMed ID: 15618294
[TBL] [Abstract][Full Text] [Related]
20. The effect of NOD2 on the microbiota in Crohn's disease.
Lauro ML; Burch JM; Grimes CL
Curr Opin Biotechnol; 2016 Aug; 40():97-102. PubMed ID: 27035071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
